Evidence map›Paper›PMID 27703532›Full record

ArticleOncology letters2016

Overlap of the cancer genome atlas and the immune epitope database.

Shaimaa Sait, Timothy Fawcett, George Blanck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shaimaa SaitDepartment of Molecular Medicine, Morsani College of Medicine, Tampa, FL 33612, USA.
Timothy FawcettDepartment of Chemical and Biomedical Engineering, College of Engineering, Research Computing University of South Florida, Tampa, FL 33620, USA.
George BlanckDepartment of Molecular Medicine, Morsani College of Medicine, Tampa, FL 33612, USA; Immunology Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutant peptides resulting from cancer drivers or passenger mutations are expected to have the potential to serve as a basis for cancer vaccines. However, a number of parameters regulate vaccine-associated immunogenicity, including the suitability of a peptide for binding to an antigen-presenting molecule or antibody. In order to obtain a basic indication of the prospect of human cancer epitope identification via current database development strategies, an overlap of the mutant

Indexed as

bioinformaticscancer immunologycollagen type II α 1extra-cellular matrix proteinsImmune Epitope Databaseimmuno-peptidome projectintegrin subunit β 3The Cancer Genome Atlas

Identifiers

PMID27703532
PMCPMC5038905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.